Return to Vaccination News Home Page __» Right-click to "open in new window"
Subscribe to the Vaccination NewsLetter
View past & current Scandals (columns by Sandy Mintz)
Search This Site using keywords
Immunization Newsbriefs (c) Copyright Information Inc., Bethesda, MD. Brought to you by the National Network for Immunization Information (NNii). Visit NNii's new website at http://www.immunizationinfo.org.
July 30, 2003
U.S. IMMUNIZATION NEWS
VaxGen Aims to Make It
San Francisco Business Times (www.sanfrancisco.bcentral.com) (06/27/03); Levine, Daniel S.
An $11 million manufacturing facility, based in South San Francisco, Calif., will produce VaxGens anthrax vaccine as well as its AIDS vaccine, which failed in clinical trials earlier this year but still has potential for the company. The facility can also produce VaxGens other products. The plant serves another purpose for VaxGen--as a training facility for workers intended to transfer to its new manufacturing facility in South Korea, part of a joint venture called Celltrion. VaxGen purposely designed the facility for easy reconfiguration as its manufacturing needs change, and the facility has a large amount of expansion space available. VaxGen currently has a $16 million National Institutes of Health contract to develop a safer anthrax vaccine, and the company plans to compete for two additional biodefense contracts. A successful outcome could lead the company into profitability next year.
Return to Vaccination News Home Page __» Right-click to "open in new window"
DISCLAIMER: All information, data, and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advice. The decision whether or not to vaccinate is an important and complex issue and should be made by you, and you alone, in consultation with your health care provider.